Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 22 studies | 32% ± 14% | |
astrocyte | 16 studies | 36% ± 16% | |
oligodendrocyte precursor cell | 12 studies | 36% ± 17% | |
glutamatergic neuron | 11 studies | 41% ± 26% | |
microglial cell | 11 studies | 38% ± 12% | |
oligodendrocyte | 11 studies | 37% ± 12% | |
fibroblast | 10 studies | 31% ± 11% | |
GABAergic neuron | 9 studies | 47% ± 21% | |
macrophage | 9 studies | 36% ± 14% | |
epithelial cell | 8 studies | 31% ± 17% | |
adipocyte | 8 studies | 32% ± 11% | |
pericyte | 7 studies | 30% ± 11% | |
T cell | 7 studies | 23% ± 6% | |
smooth muscle cell | 7 studies | 29% ± 8% | |
interneuron | 6 studies | 50% ± 20% | |
B cell | 6 studies | 23% ± 8% | |
myeloid cell | 6 studies | 25% ± 8% | |
endothelial cell of lymphatic vessel | 6 studies | 33% ± 13% | |
neuron | 5 studies | 44% ± 18% | |
cardiac muscle cell | 5 studies | 35% ± 9% | |
dendritic cell | 5 studies | 23% ± 3% | |
mast cell | 5 studies | 25% ± 6% | |
ciliated cell | 5 studies | 24% ± 7% | |
monocyte | 5 studies | 27% ± 7% | |
type I pneumocyte | 5 studies | 29% ± 9% | |
type II pneumocyte | 5 studies | 27% ± 8% | |
granule cell | 4 studies | 27% ± 5% | |
mesothelial cell | 4 studies | 29% ± 7% | |
lymphocyte | 4 studies | 31% ± 14% | |
amacrine cell | 4 studies | 28% ± 6% | |
retina horizontal cell | 4 studies | 33% ± 11% | |
retinal cone cell | 4 studies | 28% ± 7% | |
retinal rod cell | 4 studies | 31% ± 6% | |
club cell | 4 studies | 31% ± 9% | |
natural killer cell | 4 studies | 21% ± 5% | |
basal cell | 4 studies | 36% ± 22% | |
GABAergic interneuron | 3 studies | 35% ± 7% | |
progenitor cell | 3 studies | 32% ± 3% | |
plasma cell | 3 studies | 22% ± 7% | |
CD4-positive, alpha-beta T cell | 3 studies | 21% ± 2% | |
effector memory CD8-positive, alpha-beta T cell | 3 studies | 20% ± 4% | |
vein endothelial cell | 3 studies | 31% ± 17% | |
GABAergic amacrine cell | 3 studies | 28% ± 8% | |
Mueller cell | 3 studies | 36% ± 7% | |
glycinergic amacrine cell | 3 studies | 27% ± 5% | |
retinal ganglion cell | 3 studies | 30% ± 11% | |
endothelial cell of vascular tree | 3 studies | 32% ± 19% | |
hepatocyte | 3 studies | 40% ± 18% | |
ependymal cell | 3 studies | 40% ± 14% | |
alveolar macrophage | 3 studies | 31% ± 10% | |
capillary endothelial cell | 3 studies | 22% ± 5% | |
respiratory goblet cell | 3 studies | 29% ± 13% | |
goblet cell | 3 studies | 42% ± 30% | |
transit amplifying cell | 3 studies | 38% ± 29% | |
mural cell | 3 studies | 33% ± 9% | |
mucus secreting cell | 3 studies | 25% ± 7% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 100% | 3295.21 | 578 / 578 | 100% | 23.07 | 1155 / 1155 |
ovary | 100% | 4807.02 | 180 / 180 | 100% | 19.64 | 430 / 430 |
prostate | 100% | 3202.60 | 245 / 245 | 100% | 25.62 | 502 / 502 |
esophagus | 100% | 2924.36 | 1444 / 1445 | 100% | 30.46 | 183 / 183 |
breast | 100% | 4775.67 | 459 / 459 | 100% | 33.48 | 1116 / 1118 |
intestine | 100% | 3495.97 | 966 / 966 | 100% | 22.14 | 526 / 527 |
bladder | 100% | 3804.81 | 21 / 21 | 100% | 18.50 | 502 / 504 |
pancreas | 100% | 1789.91 | 328 / 328 | 99% | 17.09 | 177 / 178 |
thymus | 100% | 4111.39 | 653 / 653 | 99% | 25.63 | 601 / 605 |
uterus | 100% | 4615.43 | 170 / 170 | 99% | 19.61 | 455 / 459 |
stomach | 100% | 2591.65 | 359 / 359 | 99% | 24.68 | 283 / 286 |
kidney | 100% | 2428.81 | 89 / 89 | 98% | 19.64 | 886 / 901 |
brain | 98% | 1848.73 | 2598 / 2642 | 100% | 22.70 | 705 / 705 |
skin | 100% | 4583.66 | 1809 / 1809 | 98% | 21.60 | 463 / 472 |
adrenal gland | 100% | 2851.60 | 258 / 258 | 97% | 15.25 | 223 / 230 |
liver | 100% | 1531.88 | 226 / 226 | 86% | 8.48 | 348 / 406 |
adipose | 100% | 4372.72 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 3764.19 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 18.37 | 29 / 29 |
spleen | 100% | 3357.56 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 20.57 | 45 / 45 |
muscle | 100% | 2685.14 | 802 / 803 | 0% | 0 | 0 / 0 |
heart | 95% | 1866.82 | 820 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 91% | 14.41 | 73 / 80 |
peripheral blood | 85% | 1934.19 | 792 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_2000805 | Biological process | negative regulation of termination of RNA polymerase II transcription, poly(A)-coupled |
GO_0032786 | Biological process | positive regulation of DNA-templated transcription, elongation |
GO_0006369 | Biological process | termination of RNA polymerase II transcription |
GO_0016363 | Cellular component | nuclear matrix |
GO_0005849 | Cellular component | mRNA cleavage factor complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0000993 | Molecular function | RNA polymerase II complex binding |
GO_0043175 | Molecular function | RNA polymerase core enzyme binding |
GO_1990269 | Molecular function | RNA polymerase II C-terminal domain phosphoserine binding |
GO_0005515 | Molecular function | protein binding |
GO_0003729 | Molecular function | mRNA binding |
GO_0003723 | Molecular function | RNA binding |
Gene name | SCAF8 |
Protein name | SR-related CTD associated factor 8 SR-related and CTD-associated factor 8 (CDC5L complex-associated protein 7) (RNA-binding motif protein 16) |
Synonyms | CCAP7 RBM16 KIAA1116 |
Description | FUNCTION: Anti-terminator protein required to prevent early mRNA termination during transcription . Together with SCAF4, acts by suppressing the use of early, alternative poly(A) sites, thereby preventing the accumulation of non-functional truncated proteins . Mechanistically, associates with the phosphorylated C-terminal heptapeptide repeat domain (CTD) of the largest RNA polymerase II subunit (POLR2A), and subsequently binds nascent RNA upstream of early polyadenylation sites to prevent premature mRNA transcript cleavage and polyadenylation . Independently of SCAF4, also acts as a positive regulator of transcript elongation . . |
Accessions | ENST00000367178.8 [Q9UPN6-1] ENST00000417268.3 ENST00000367186.7 [Q9UPN6-2] A0A0A0MT33 Q9UPN6 |